Someone may become a victim of the evil eye by virtue of an "unfavorable celestial configuration" at the time of victims birth, "according to some scholars".Among the rituals to ward off the evil eye are to say "TabarakAllah" (تبارك الله) ("Blessings of God") or "MashaAllah" (ما شاء الله) ("God has willed it") if a compliment is to be made. By geographic region
Caribbean/West Indies
In Trinidad and Tobago, the evil eye is called maljo (from French mal yeux, meaning bad eye). The term is used in the infinitive (to maljo) and as a noun (to have/get maljo) referring to persons who have been afflicted. Maljo may be passed on inadvertently, but is believed to be more severe when coming from an envious person or one with bad intentions. It is thought to happen more readily when a person is stared at- especially while eating food. A person who has been taken by the ‘bad eye’ may experience unexplained illness or misfortune. In traditional rural legends, ‘The general belief is that doctors cannot cure maljo----only people who know prayers can "cut" the maljo and thus cure the victim.’There are several secular approaches to combatting maljo, but more extreme cases are usually referred to as spiritual rituals, with a particularly strong influence from the Hindu religion. In non-religious respects, there is a strong cultural association between the evil eye and the color blue. It is believed to ward off maljo when worn as clothing or accessories, so much so that some striking shades are referred to as ‘maljo blue’.
"Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines". Mol. Pharm. 16 (7): 3040–3052. doi:10.1021/acs.molpharmaceut.9b00274. PMC 6620786. PMID 31117741. Gebreyohannes YK, Wozniak A, Zhai ME,  et al. (January 2019). "Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors". Clin. Cancer Res. 25 (2): 609–618. doi:10.1158/1078-0432.CCR-18-1858. PMID 30274985. External links
"Avapritinib". Drug Information Portal. U.S. National Library of Medicine (NLM). "Avapritinib". NCI Dictionary of Cancer Terms. National Cancer Institute. "Avapritinib". National Cancer Institute. 28 January 2020. Clinical trial number NCT02508532 for "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors" at ClinicalTrials.gov
Clinical trial number NCT02561988 for "(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies" at ClinicalTrials.gov
Clinical trial number NCT03580655 for "(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis" at ClinicalTrials.gov